It is widely acknowledged that the size, shape and surface characteristics of nanomaterials greatly determine their biological fate in vivo, consequently affecting their bioavailability when used as nanomedicines or their potential adverse effects. More than 30 years ago, Illum et al. demonstrated that smaller polystyrene spheres (< 1 µm) were more likely to be taken up by the mononuclear phagocyte system, whereas larger particles (> 1 µm) were mechanically filtered by the lung capillary beds . Whilst applications such as thin films, composites and electronic devices privilege the use of large, micrometre-sized GBMs , recent reviews suggest that chemically modifying the surface of GBMs and reducing their lateral dimensions are two useful strategies to favour their behaviour in physiological milieu and thus improve their biocompatibility . Some reports have also confirmed that GO of greater lateral dimensions has a greater potential of inducing inflammatory responses . Furthermore, the flake thickness has been proven to have an impact on the biodistribution after intravenous administration, as thin GO flakes (~1.2 nm) were found to accumulate less and be more rapidly excreted through the urinary tract than the thick ones (~20 nm) , demonstrating an optimal circulation half-life and clearance for thinner materials when considered as nanomedicines.